The present invention relates to compounds with vasopressin V1a antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin V1a antagonists for the treatment of certain physiological disorders, such as Raynauds disease and dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea).